TGTX

TG Therapeutics, Inc.

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

TG Therapeutics, Inc. (TGTX) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 D+ (1.5) B- (3.1) B- (3.1) A (4.2) C+ (2.6) B- (2.9)
2026-11-08 C- (2.1) B (3.2) B (3.2) A- (3.9) C+ (2.6) B- (3.0)
2026-11-01 C (2.2) B (3.2) B (3.2) A (4.2) C+ (2.7) B- (3.1)
2026-10-25 C (2.3) B (3.2) B (3.2) B (3.5) C+ (2.6) B- (3.0)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe